Senyawa Bioaktif Herpetofauna pada Penderita Diabetes Mellitus dan Hipertensi: Tinjauan Secara Patofisiologi

https://doi.org/10.31957/jbp.521

Authors

  • Aditya K. Karim Laboratorium Fisiologi Hewan, Jurusan Biologi, FMIPA Universitas Cenderawasih, Jayapura
  • Rury Eprilurahman Laboratorium Taksonomi Hewan, Fakultas Biologi Universitas Gadjah Mada Yogyakarta
  • Laksmindra Fitria Laboratorium Fisiologi Hewan, Fakultas Biologi Universitas Gadjah Mada Yogyakarta
  • Paul J. Kawatu Laboratorium Fisiologi Hewan, Jurusan MIPA, FKIP Universitas Cenderawasih, Jayapura

Abstract

Amphibians and reptiles (herpetofauna groups) produced of many compounds. The herpetofauna and their chemical compounds have been the subject of intense research interest for many years due to their potential in medical application and in lead compound development for new drugs. A number of different types of compounds have been identified from the glandular skin secretions of amphibians and venom or saliva of reptiles. These compounds have been shown to be active against gram-negative and gram-positive bacteria, fungi, enveloped viruses, diabetes mellitus, hypertension and cardiovascular disorder.

Key words: Herpetofauna, diabetes mellitus, hypertension, drugs, pathophysiology

Downloads

Download data is not yet available.

Author Biographies

Aditya K. Karim, Laboratorium Fisiologi Hewan, Jurusan Biologi, FMIPA Universitas Cenderawasih, Jayapura

Laboratorium Fisiologi Hewan, Jurusan Biologi, FMIPA Universitas Cenderawasih, Jayapura

Rury Eprilurahman, Laboratorium Taksonomi Hewan, Fakultas Biologi Universitas Gadjah Mada Yogyakarta

Laboratorium Taksonomi Hewan, Fakultas Biologi Universitas Gadjah Mada Yogyakarta

Laksmindra Fitria, Laboratorium Fisiologi Hewan, Fakultas Biologi Universitas Gadjah Mada Yogyakarta

Laboratorium Fisiologi Hewan, Fakultas Biologi Universitas Gadjah Mada Yogyakarta

Paul J. Kawatu, Laboratorium Fisiologi Hewan, Jurusan MIPA, FKIP Universitas Cenderawasih, Jayapura

Laboratorium Fisiologi Hewan, Jurusan MIPA, FKIP Universitas Cenderawasih, Jayapura 

References

Abdel-Wahab, Y.H., L. Marenah, D.V. Orr, C. Shaw, and P.R. Flatt. 2005. Isolation and Structural Characterisation of A Novel 13-Amino Acid Insulin-Releasing Peptide from The Skin Secretion of Agalychnis calcarifer. Biol. Chem. 386: 581–587.

Armstrong, D.G. and L.A. Lavery. 1998. Diabetic foot ulcers: Prevention, diagnosis and classification. Am Fam Physician. 57(6): 1325-1332.

American Diabetes Association 2011. Diagnosis and classification of diabetes mellitus. Diabetes Care. 35 (Suppl-1): S62-S69.

American Diabetes Association 2012. Standards of medical care in diabetes-2012. Diabetes Care. 35(Suppl-1): S11-S63.

Boulton, A.J. 2000. The diabetic foot: a global view. Diabetes Metab Res Rev. 16(Suppl-1): S2-S5.

Brand, G.D., F.C. Krause, L.P. Silva, J.R. Leite, J.A. Melo, M.V. Prates, J.B. Pesquero, E.L. Santos, C.R. Nakaie, C.M. Costa-Neto. and C. Bloch. 2006. Bradykinin-related peptides from Phyllomedusa hypochondrialis. Peptides. 27(9): 2137-2146.

Chi, C.W., S.Z. Wang, L.G. Xu, M.Y. Wang, S.S. Lo. and W.D. Huang. 1985. Structure-function studies on the bradykinin potentiating peptide from Chinese snake venom (Agkistrodon halys Pallas). Peptides. 6(Suppl 3): 339-342.

Chobanian, A.V., C.C. Haudenschild, C. Nickerson. and R. Drago. 1990. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension (Dallas). 15:327-331.

Conceicao, K., K. Konno, R. Lopes de Melo, M.M. Antoniazzi, C. Jared, J.M. Sciani, I.M. Conceicao, B.C. Prezoto, A.C. Martins de Camargo. and D.C. Pimenta. 2007. Isolation and characterization of a novel bradykinin potentiating peptide (BPP) from the skin secretion of Phyllomedusa hypochondrialis. Peptides. 28: 515-523.

Corwin, E.J. 2009. Patofisiologi. Ed.3th. EGC. Penerbit Buku Kedokteran. Jakarta. Hal.441-520.

Defronzo, R.A., R.E. Ratner, J. Han, D.D. Kim, M.S. Fineman. and A.D. Baron. 2005. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 28(5): 1092-1100.

Eng, J., W.A. Kleinman, L. Singh, G. Singh. and J.P. Raufmanll. 1992. Isolation and characterizationo of exendin-4, and exendin-3 analogue, from Heloderma suspecturn venom. J Biol Chem. 267(11): 7402-7406.

Fernandez, J.H., G. Neshich. and A.C.M. Camargo. 2004. Using bradykinin-potentiating peptide structures to develop new antihypertensive drugs. Genet Mol Res. 3 (4): 554-563.

Frykberg, R.G. 1998. Diabetic foot ulcers: current concepts. J Foot Ankle Surg. 37: 440-446.

Frykberg, R.G., D.G. Armstrong, J. Giurini, A. Edwards, M. Kravette. and S. Kravitz. 2000. Diabetic foot disorders: a clinical practice guideline. American College of Foot and Ankle Surgeons. J Foot Ankle Surg. 39(Suppl-5): S1-60.

Frykberg, R.G. 2002. Diabetic foot ulcers: pathogenesis and management. Am Fam Physician. 66(9): 1655-1663.

Ge, Y., D.L. MacDonald, K.J. Holroyd, C. Thornsberry, H. Wexler. and M. Zasloff. 1999a. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother. 43(4): 4782-4788.

Ge, Y., D.L. MacDonald, M.M. Henry, H.I. Hait, K.A. Nelson, B.A. Lipsky, M. Zasloff. and K.J. Holroyd. 1999b. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn Microbiol Infect Dis. 35:45–53.

Gedulin, B.R., S.E. Nikoulina, P.A. Smith, G. Gedulin, L.L. Nielsen, A.D. Baron, D.G. Parkes. and A.A. Young. 2005. Exenatide (exendin-4) improves insulin sensitivity and (beta)-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology. 146(4): 2069-2076.

Godsel, L.M., J.S. Leon. and D.M. Engman. 2003. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in experimental myocarditis. Curr Pharm. 9: 723-735.

Ianzera, D., K. Konnoa, R. Marques-Portoa, F.C.V. Portaroa, R. Stöcklinb, A.C.M. de Camargoa. and D.C. Pimentaa. 2004. Identification of five new bradykinin potentiating peptides (BPPs) from Bothrops jararaca crude venom by using electrospray ionization tandem mass spectrometry after a two-step liquid chromatography. Peptides. 25(7): 1085–1092.

Jackson, W.E., D.L. Holmes, S.K. Garg, S. Harris. and H.P. Chase. 1992. Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy. Ann Opthalmol. 24: 99-103.

Karim, A.K., Z.A. Wasaraka, L.Y. Chrystomo dan E. Indraya-ni. 2012. Peran herpetofauna dalam Bidang Kese-hatan: Peluang dan Tantangan. Jurnal Biologi Papua. 4(1): 37-46.

Kementerian Kesehatan Republik Indonesia. 2012a. Tahun 2030 Prevalensi diabetes melitus di Indonesia mencapai 21,3 Juta Orang.http://www.depkes.go.id/index.php/ berita/press-release/414-tahun-2030-prevalensi-dia betes-melitus-di-indonesia-mencapai-213-juta-rang.html (diakses tanggal 16 November 2012).

Kementerian Kesehatan Republik Indonesia. 2012b. Masalah hipertensi di Indonesia http://www.depkes.go.id /index.php/berita/press-release/1909-masalah hiper-tensi-di-indonesia.html (diakses tanggal 16 November 2012).

Lees, K.R., R.J. MacFadyen, J.K. Doig. and J.L. Reid. 1993. Role of angiotensin in the extravascular system. J Human Hypertension. 7 (Suppl 2): S7-12.

Lewis, E.J. 1995. Captopril and diabetic nephropathy. J Am Med Assoc. 273: 1831.

Lipsky, B.A., K.J. Holroyd. and M. Zasloff. 2008. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: A randomized, controlled, double-blinded, multicenter trial of pexi-ganan cream. Clin Infect Dis. 47: 1537-1545.

Marenah L., P.R. Flatt, D.F. Orr, S. McClean, C. Shaw. and Y.H.A. Abdel-Wahab. 2004a. Skin secretion of the toad Bombina variegata contains multiple insulin-releasing peptides including bombesin and entirely novel insulinotropic structures. Biol. Chem. 385: 315-321.

Marenah, L, P.R. Flatt, D.F. Orr, S. McClean, C. Shaw. and Y.H.A. Abdel-Wahab. 2004b Isolation and characteri-sation of an unexpected class of insulinotropic peptides in the skin of the frog Agalychnis litodryas. Regulatory Peptide. 120: 33–38.

Marenah, L., P..R. Flatt, D.F. Orr, C. Shaw. and Y.H.A. Abdel-Wahab. 2006. Skin secretions of Rana saharica frogs reveal antimicrobial peptides esculentins-1 and -1B and brevinins-1E and -2EC with novel insulin releasing activity. J. Endocrinology. 188: 1–9.

Martin, M.F.R., K.E. Surrall, F. McKenna, J.S. Dixon, H.A. Bird. and V. Wright. 1984. Captopril: a new treatment for rheumatoid arthritis?. Lancet. 8390: 1325-1328.

Mealey, B.L. and G.L. Ocampo. 2007. Diabetes mellitus and eriodontal disease. Periodontology. 44: 127-153.

Nielsen, L.L., A.A. Young. And D.G. Parkes. 2004. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regulatory Peptides. 117(2): 77–88.

Nauck, M.A. and J.J. Meier. 2005. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regulatory Peptides. 128(2): 135-148.

Patlak, M. 2003. From viper’s venom to drugs design: Treating hypertension. FASEB.J. 18: 421-426.

Primarck, B,R., S. Jatna, I. Mochammad. dan K. Padmi. 1998. Biologi konservasi. Yayasan Obor Indonesia. Jakarta.

Reiber, G.E., E.J. Boyko. and D.G. Smith. 1995. Lower extremity foot ulcers and amputations in diabetes. In: National Diabetes Data Group (U.S.). Diabetes in America. 2d ed. Bethesda, Md.: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, NIH publication no. 95-1468.

Riaz, S. 2009. Diabetes mellitus. Sci Res Essay. 4(5): 367-373.

Rioli, V., B.C. Prezoto, K. Konno, R.L. Melo, C.F. Klitzke, E.S. Ferro, M. Ferreira-Lopes, A.C. Camargo. and F.C. Portaro. 2008. A novel bradykinin potentiating peptide isolated from Bothrops jararacussu venom using catally-tically inactive oligopeptidase EP24.15. FEBS J. 275(10): 2442–2454.

Sernia, C. 2001. A critical appraisal of the intrinsic pancreatic angiotensin- generating system. JOP. 2(1): 50–55.

Singh, S. 2011. The Genetic of type 2 diabetes mellitus; Review. J Sci Res. 55: 35-48.

Smith, C.G. and J.R. Vane. 2003. The discovery of captopril. The FASEB J. 17(8): 788-789.

Snehalatha and Ramachnadaran. 2009. Insight into the mechanism of primary prevention of type 2 Diabetes: improvement in insulin sensitivity and beta cell function. “Genetic and epigenetic basis of complex diseases“ Conference in Centre for Cellular and Molecular Biology; December, 2009.

Stumvoll, M., B.J. Goldstein. and T.W. van Haeften. 2005. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 365: 1333-1346.

Triplitt, C. and E. Chiquette. 2006. Exenatide: From The Gila Monster to The Pharmacy. J Am Pharm Assoc. 46(1): 44-52.

Varagic, J. and E.D. Frohlich. 2003. Local cardiac renin-angiotensin system: hypertension and cardiac failure. J Mol Cell Cardiol. 34 (11): 1435-1442.

Weir, M.R. and V.J. Dzau. 2000. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens. 12 (3): 205S-213S.

WHO. 2005. Clinical guidelines for the management of hypertension/Edited by Oussama M.N. Khatib, Mohamed Sayed El-Guindy. WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland. 97p.

WHO. 2006. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland. 46p.

Wild, S., G. Roglic, A. Green, R. Sicree. and H. King. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 27: 1047-1053.

Wysocki, P.J., E.P. Kwiatkowska, U. Kazimierczak, W. Suchorska, D.W. Kowalczyk. and A. Mackiewicz. 2006. Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice. Clin Cancer Res. 12: 4095-4102.

Yoon, S.S., V. Burt, T. Louis. and M.D. Carroll. 2012. Hypertension among adults in The United States, 2009-2010. NCHS Data Brief. No. 107. pp: 1-7.

Young, J.B. 1994. Angiotensin-converting enzyme inhibitors in heart failure: new strategies justified by recent clinical trials. Int J Cardiol. 43: 151-163.

Downloads

Published

2018-10-13

Issue

Vol. 5 No. 1 (2013)

Section

Research Articles

License

1. Copyright Policy

Jurnal Biologi Papua is committed to promoting the dissemination, accessibility, and responsible reuse of scholarly research in biology and related disciplines.

Under this policy, authors retain copyright ownership of their published articles and grant Jurnal Biologi Papua the non-exclusive right of first publication.

Authors retain the right to use, distribute, reproduce, and share their scholarly work in accordance with the applicable publication license.

The journal acknowledges the intellectual contributions of authors and respects their moral rights, including the right to be properly identified as creators of their work.

2. Publication License

Articles published under this policy are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).

License URL: https://creativecommons.org/licenses/by/4.0/

Under this license, users are permitted to:

  1. Share: Copy and redistribute published articles in any medium or format.

  2. Adapt: Remix, transform, and build upon published materials for any purpose, including commercial purposes.

  3. Redistribute: Make articles available through repositories, websites, databases, and other scholarly platforms.

These permissions are subject to the Creative Commons Attribution 4.0 International License.

Users must provide appropriate credit to the original authors, include a link to the license, and indicate whether changes have been made.

Reuse must not imply endorsement by the authors or publisher.

3. Rights of Authors

Authors publishing in Jurnal Biologi Papua retain the following rights:

  1. Copyright ownership of their original scholarly work.

  2. The right to distribute and share their published articles.

  3. The right to deposit their articles in institutional or subject repositories.

  4. The right to reuse their work in subsequent scholarly publications, subject to appropriate acknowledgment and applicable ethical standards.

  5. The right to share their work for teaching, research, academic collaboration, and other lawful purposes.

Authors must acknowledge the original publication in Jurnal Biologi Papua when distributing or reusing the published version.

4. Rights of the Publisher

Authors grant Jurnal Biologi Papua the non-exclusive right to publish, disseminate, archive, and preserve accepted manuscripts.

The journal may reproduce and distribute the published version through its official website and authorized indexing, archiving, and scholarly dissemination services.

The publisher is responsible for maintaining the integrity of published content and accurately displaying copyright and licensing information.

5. Open Access Policy

Jurnal Biologi Papua supports immediate open access to scholarly research.

Articles published under this policy are freely accessible to readers without subscription requirements or access fees.

The journal encourages the responsible dissemination and reuse of published research to support scientific progress, academic collaboration, and the broader exchange of knowledge.

Published content may be accessed, downloaded, shared, and reused in accordance with the applicable Creative Commons license.

6. Third-Party Materials

Authors are responsible for ensuring that all materials included in their manuscripts comply with applicable copyright and intellectual property laws.

Permission must be obtained when required for the use of third-party figures, photographs, tables, illustrations, or other copyrighted materials.

Materials excluded from the article's Creative Commons license must be clearly identified with their applicable copyright and permission notices.

The journal's publication license does not override the rights of third-party copyright holders.

7. Repository and Self-Archiving Policy

Authors are permitted and encouraged to deposit and share their published articles through institutional repositories, academic repositories, and personal or institutional websites.

Authors must provide appropriate acknowledgment of the article's original publication in Jurnal Biologi Papua, including its citation information and DOI where available.

Repository deposits and subsequent distribution must comply with the license applicable to the relevant version of the article.

8. Licensing Information and Article Metadata

The applicable copyright holder and publication license should be clearly identified on each published article's webpage.

Where supported, licensing information should also be included in article metadata and the published PDF.

The journal is committed to maintaining accurate and consistent licensing information across its online publishing platform and scholarly indexing services.

9. Policy Application and Previously Published Articles

This policy applies to manuscripts accepted following its formal adoption by the journal and publisher.

Articles published before the adoption of this policy remain subject to the copyright arrangements and licenses applicable at the time of their publication, unless a valid change is authorized by the relevant rights holders.

The journal will not apply a new license retroactively without the necessary authorization.

10. Policy Commitment

Jurnal Biologi Papua is committed to transparent copyright arrangements, responsible open access publishing, and respect for intellectual property rights.

The journal will periodically review its copyright and licensing practices to maintain consistency with recognized standards of scholarly communication.

References

Creative Commons Attribution 4.0 International License: https://creativecommons.org/licenses/by/4.0/

Directory of Open Access Journals (DOAJ): https://doaj.org/apply/copyright-and-licensing/